ANGIOTENSIN RECEPTOR TOPOLOGY AND FUNCTION
ANGIOTENSIN RECEPTOR TOPOLOGY AND FUNCTION
批准号:
2017118
负责人:
SHIOW-SHIH TANG
金额:
$21.96万
依托单位国家:
美国
项目类别:
财政年份:
1997
资助国家:
美国
项目状态:
已结题
起止时间:
1997-05-01 至 2001-04-30
中文摘要
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION (Adapted from the Applicant's Abstract): The renal proximal
tubule (PT) plays an important role in homeostasis by reabsorption of salt
and water and yet is often exposed to toxic and ischemic insults, and thus
constantly undergoes injury and repair. Indeed, PT injury is a major cause
of renal failure. PT contains a complete renin-angiotensin system (RAS) and
produces endogenous angiotensin II (Ang II). Angiotensin converting enzyme
inhibitor effectively slows progression of chronic renal insufficiency, and
may ameliorate tubulointerstitial injury. Therefore, the RAS and its
product, Ang II, may play an important role in PT injury and repair. The
principal investigator proposes to use lines (that he has developed and
characterized) of immortalized rat proximal tubule cells (IRPTC) from
weanling rat kidney that express all the components of the RAS, including
Ang II receptor subtypes AT1 and AT2, as a model. The studies will focus on
the role of Ang II in PT injury and repair. The overall hypothesis is that
PT injury involves modulation of both AT1 and AT2 in PT; furthermore, that
AT1 receptor activation leads to cell growth and proliferation, while AT2
inhibits growth as well as AT1 expression, later leading to programmed cell
death. Using an IRPTC oxidant injury model, the Specific Aims proposed will
test the following hypotheses: 1) that PT injury initially upregulates both
AT1 and AT2 expression; 2) that PT injury induces release of endogenous Ang
II which influences subsequent transcription of both AT1 and AT2 receptors;
and 3) that during repair there is crosstalk between AT2 and AT1, i.e., that
AT2 receptor activation inhibits AT1 expression through intracellular Na+
loading, and later AT2 induces programmed cell death.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
ANGIOTENSIN RECEPTOR TOPOLOGY AND FUNCTION
-
批准号:2701199
-
项目类别:
-
资助金额:$22.62万
-
财政年份:1997
-
负责人:SHIOW-SHIH TANG
-
依托单位:
ANGIOTENSIN RECEPTOR TOPOLOGY AND FUNCTION
-
批准号:2905833
-
项目类别:
-
资助金额:$23.3万
-
财政年份:1997
-
负责人:SHIOW-SHIH TANG
-
依托单位:
ANGIOTENSIN RECEPTOR TOPOLOGY AND FUNCTION
-
批准号:6177503
-
项目类别:
-
资助金额:$24.0万
-
财政年份:1997
-
负责人:SHIOW-SHIH TANG
-
依托单位:
NUCLEAR EFFECTS OF ANGIOTENSIN ON VASCULAR SMOOTH MUSCLE
-
批准号:3361598
-
项目类别:
-
资助金额:$20.31万
-
财政年份:1990
-
负责人:SHIOW-SHIH TANG
-
依托单位:
NUCLEAR EFFECTS OF ANGIOTENSIN ON VASCULAR SMOOTH MUSCLE
-
批准号:3361601
-
项目类别:
-
资助金额:$11.32万
-
财政年份:1990
-
负责人:SHIOW-SHIH TANG
-
依托单位:
NUCLEAR EFFECTS OF ANGIOTENSIN ON VASCULAR SMOOTH MUSCLE
-
批准号:2220865
-
项目类别:
-
资助金额:$20.7万
-
财政年份:1990
-
负责人:SHIOW-SHIH TANG
-
依托单位:
NUCLEAR EFFECTS OF ANGIOTENSIN ON VASCULAR SMOOTH MUSCLE
-
批准号:3361600
-
项目类别:
-
资助金额:$20.42万
-
财政年份:1990
-
负责人:SHIOW-SHIH TANG
-
依托单位:
NUCLEAR EFFECTS OF ANGIOTENSIN ON VASCULAR SMOOTH MUSCLE
-
批准号:3361596
-
项目类别:
-
资助金额:$13.48万
-
财政年份:1989
-
负责人:SHIOW-SHIH TANG
-
依托单位:
NUCLEAR EFFECTS OF ANGIOTENSIN ON VASCULAR SMOOTH MUSCLE
-
批准号:3361599
-
项目类别:
-
资助金额:$2.5万
-
财政年份:1989
-
负责人:SHIOW-SHIH TANG
-
依托单位:
国内基金
海外基金
登录
查看更多内容
Epac1/2通过蛋白酶体调控中性粒细胞NETosis和Apoptosis在急性肺损伤中的作用研究
-
批准号:LBY21H010001
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2020
-
负责人:郑绪阳
-
依托单位:
基于Apoptosis/Ferroptosis双重激活效应的天然产物AlbiziabiosideA的抗肿瘤作用机制研究及其结构改造
-
批准号:81703335
-
项目类别:青年科学基金项目
-
资助金额:20.0万元
-
批准年份:2017
-
负责人:卫高菲
-
依托单位:
双肝移植后Apoptosis和pyroptosis在移植物萎缩差异中的作用和供受者免疫微环境变化研究
-
批准号:81670594
-
项目类别:面上项目
-
资助金额:58.0万元
-
批准年份:2016
-
负责人:陈昊
-
依托单位:
Serp-2 调控apoptosis和pyroptosis 对肝脏缺血再灌注损伤的保护作用研究
-
批准号:81470791
-
项目类别:面上项目
-
资助金额:73.0万元
-
批准年份:2014
-
负责人:董家鸿
-
依托单位:
Apoptosis signal-regulating kinase 1是七氟烷抑制小胶质细胞活化的关键分子靶点?
-
批准号:81301123
-
项目类别:青年科学基金项目
-
资助金额:23.0万元
-
批准年份:2013
-
负责人:王海莲
-
依托单位:
APO-miR(multi-targeting apoptosis-regulatory miRNA)在前列腺癌中的表达和作用
-
批准号:81101529
-
项目类别:青年科学基金项目
-
资助金额:22.0万元
-
批准年份:2011
-
负责人:陈雪芹
-
依托单位:
放疗与细胞程序性死亡(APOPTOSIS)相关性及其应用研究
-
批准号:39500043
-
项目类别:青年科学基金项目
-
资助金额:9.0万元
-
批准年份:1995
-
负责人:梁克
-
依托单位: